NEXEL Co., Ltd. was established in 2012 as a spin-off from Korea University in Seoul, South Korea, specializing in induced pluripotent stem cell (iPSC) technology.

Our philosophy is to “Make a Better Place” by supporting innovative research around the world through high-quality iPSC-derived somatic cell products and preclinical safety assessment services by utilizing our high-quality iPSC cell products.

Nexel currently commercializes iPSC-derived ventricular cardiomyocytes, neurons and hepatocytes. In order to carry out more in-depth innovative research, we are in the process of launching 3D organoid models, including cardiac organoids and heart organoids.

NEXEL, Co., Ltd. aims to grow as a global leader in the bio-industry. This is embodied by its enthusiastic and passionate employees and a corporate culture that supports creative innovation.. Based on state-of-the-art technology, we plan to manufacture higher quality products and improve the research environment of our valuable customers and collaborators. We also aim to directly improve the quality of life of patients affected by disease. We are investing our resources in novel protein-based therapies for previously untreatable indications.

At NEXEL, we truly believe that through our work, we will leave the world a better place than the one we found it.